Filana Therapeutics Receives FDA Clinical Hold Lift for Simufilam

Filing content

Filana Therapeutics has received FDA clearance to lift the clinical hold on its simufilam IND, enabling the company to proceed with a Phase 2a study in TSC-related epilepsy, with patient screening expected by Q1 2027.